[go: up one dir, main page]

WO2008036135A3 - STRUCTURE CRISTALLINE DE CRIg ET D'UN COMPLEXE C3b:CRIg - Google Patents

STRUCTURE CRISTALLINE DE CRIg ET D'UN COMPLEXE C3b:CRIg Download PDF

Info

Publication number
WO2008036135A3
WO2008036135A3 PCT/US2007/012816 US2007012816W WO2008036135A3 WO 2008036135 A3 WO2008036135 A3 WO 2008036135A3 US 2007012816 W US2007012816 W US 2007012816W WO 2008036135 A3 WO2008036135 A3 WO 2008036135A3
Authority
WO
WIPO (PCT)
Prior art keywords
crig
complex
crystal structure
stigma
subunits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/012816
Other languages
English (en)
Other versions
WO2008036135A2 (fr
Inventor
Phillip Hass
Kenneth Katschke Jr
Micah Steffek
Lookeren Campagne Menno Van
Chris Wiesmann
Jianping Yin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to CA002654438A priority Critical patent/CA2654438A1/fr
Priority to JP2009513268A priority patent/JP2010505743A/ja
Priority to AU2007297869A priority patent/AU2007297869A1/en
Priority to NZ573176A priority patent/NZ573176A/en
Priority to EP07852376A priority patent/EP2024391A2/fr
Publication of WO2008036135A2 publication Critical patent/WO2008036135A2/fr
Publication of WO2008036135A3 publication Critical patent/WO2008036135A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Metallurgy (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

La présente invention concerne la détermination de la structure cristalline du récepteur spécifique des macrophages, CRIg (auparavant appelé STIgMA), et de son complexe avec les sous-unités C3b et C3c du complément C3 (complexes C3b:CRIg et C3c:CRIg). L'invention concerne également l'utilisation de la structure cristalline de CRIg ou du complexe C3b:CRIg pour le criblage et l'identification de molécules structuralement et/ou fonctionnellement associées à CRIg, telles que des agonistes et des antagonistes de CRIg.
PCT/US2007/012816 2006-06-01 2007-05-30 STRUCTURE CRISTALLINE DE CRIg ET D'UN COMPLEXE C3b:CRIg Ceased WO2008036135A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002654438A CA2654438A1 (fr) 2006-06-01 2007-05-30 Structure cristalline de crig et d'un complexe c3b:crig
JP2009513268A JP2010505743A (ja) 2006-06-01 2007-05-30 ＣＲＩｇ及びＣ３ｂ：ＣＲＩｇ複合体の結晶構造
AU2007297869A AU2007297869A1 (en) 2006-06-01 2007-05-30 Crystal structure of CRig and C3b: CRig complex
NZ573176A NZ573176A (en) 2006-06-01 2007-05-30 CRYSTAL STRUCTURE OF CRIg AND C3b:CRIg COMPLEX
EP07852376A EP2024391A2 (fr) 2006-06-01 2007-05-30 STRUCTURE CRISTALLINE DE CRIg ET D'UN COMPLEXE C3b:CRIg

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US81027106P 2006-06-01 2006-06-01
US60/810,271 2006-06-01
US80622506P 2006-06-29 2006-06-29
US60/806,225 2006-08-03
US83936306P 2006-08-21 2006-08-21
US60/839,363 2006-08-21

Publications (2)

Publication Number Publication Date
WO2008036135A2 WO2008036135A2 (fr) 2008-03-27
WO2008036135A3 true WO2008036135A3 (fr) 2008-10-02

Family

ID=39106149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/012816 Ceased WO2008036135A2 (fr) 2006-06-01 2007-05-30 STRUCTURE CRISTALLINE DE CRIg ET D'UN COMPLEXE C3b:CRIg

Country Status (5)

Country Link
EP (1) EP2024391A2 (fr)
JP (1) JP2010505743A (fr)
AU (1) AU2007297869A1 (fr)
CA (1) CA2654438A1 (fr)
WO (1) WO2008036135A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2280996T3 (pl) * 2008-05-06 2017-07-31 Genentech Inc WARIANTY CRIg O DOJRZAŁYM POWINOWACTWIE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012703A2 (fr) * 1998-08-27 2000-03-09 Incyte Pharmaceuticals, Inc. Molecules associees au transport de proteines
WO2006042329A2 (fr) * 2004-10-12 2006-04-20 Genentech, Inc. Prevention et traitement de troubles associes au complement

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0739904A1 (fr) 1989-06-29 1996-10-30 Medarex, Inc. Réactifs bispécifiques pour le traitement du SIDA
WO1992020373A1 (fr) 1991-05-14 1992-11-26 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
JP4300286B2 (ja) * 2002-02-07 2009-07-22 独立行政法人産業技術総合研究所 可溶化補体レセプタータイプ１の結晶

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012703A2 (fr) * 1998-08-27 2000-03-09 Incyte Pharmaceuticals, Inc. Molecules associees au transport de proteines
WO2006042329A2 (fr) * 2004-10-12 2006-04-20 Genentech, Inc. Prevention et traitement de troubles associes au complement

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HELMY ET AL: "CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens; Supplemental Data", CELL, 10 March 2006 (2006-03-10), XP002487601, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/MiamiMultiMediaURL/B6WSN-4JF8PW0-D/B6WSN-4JF8PW0-D-J/7051/6fb838b149b637f4b1feeaafe57ac23c/mmc1.pdf> *
HELMY KARIM Y ET AL: "CRIg: A macrophage complement receptor required for phagocytosis of circulating pathogens", CELL, vol. 124, no. 5, March 2006 (2006-03-01), pages 915 - 927, XP002471199, ISSN: 0092-8674 *
MOLINA HECTOR ET AL: "Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2", JOURNAL OF IMMUNOLOGY, vol. 153, no. 2, 1994, pages 789 - 795, XP002487602, ISSN: 0022-1767 *
WIESMANN CHRISTIAN ET AL: "Structure of C3b in complex with CRIg gives insights into regulation of complement activation", NATURE (LONDON), vol. 444, no. 7116, November 2006 (2006-11-01), pages 217 - 220, XP002471200, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2008036135A2 (fr) 2008-03-27
AU2007297869A1 (en) 2008-03-27
EP2024391A2 (fr) 2009-02-18
JP2010505743A (ja) 2010-02-25
AU2007297869A8 (en) 2009-01-08
CA2654438A1 (fr) 2008-03-27

Similar Documents

Publication Publication Date Title
EP1993560A4 (fr) Antagonistes de recepteur cannabinoide/agonistes inverses utiles dans le traitement de l&#39;obesite
EP2551270A3 (fr) Dérivés pyrazolopyrimidine en tant qu&#39;antagonistes de la pi3 kinase
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2008008887A3 (fr) Composés chimiques
MX2009010833A (es) Procedimiento para isomerizar un (hidrohalo) fluoroalqueno.
WO2007131219A3 (fr) Antagonistes /agonistes inverses des récepteurs cannabinoïdes utilisés pour traiter des troubles du métabolisme, notamment l&#39;obésité et le diabète
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
WO2010077898A3 (fr) Trans-chloro-3,3,3-trifluoropropène destiné à être utilisé dans des applications de refroidisseurs
EP2367793B8 (fr) Agonistes de récepteurs gpr 120 et leurs applications
WO2008021851A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses pour les récepteurs d&#39;opioïdes
WO2008019147A3 (fr) Utilisation d&#39;exendines et d&#39;agonistes d&#39;exendines et d&#39;agonistes des récepteurs du glp-1 pour modifier la concentration de fibrinogène
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
WO2009156462A3 (fr) Composés organiques
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d&#39;utilisation
NO20083153L (no) Kjemiske forbindelser
WO2008021849A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses à des récepteurs d&#39;opioïdes
MY150542A (en) Cmet inhibitors
BRPI0911067B8 (pt) métodos e sistemas para determinar a presença ou ausência de um analito em uma amostra de líquido
EA201170227A1 (ru) Имидазолкарбоксамиды
WO2010005982A3 (fr) Biomarqueurs multiplexés de résistance à l&#39;insuline
WO2007056681A3 (fr) Procedes d&#39;administration d&#39;agents hypoglycemiques
GB0812642D0 (en) Compounds
BRPI0912229A2 (pt) mistura para remoção de oxigênio, composição, artigo, mistura padrão, e, uso de uma mistura
WO2006116622A3 (fr) Nouveaux procedes et dispositifs d&#39;evaluation de substances toxiques
IL201012A0 (en) Quinoline derivatives as crth2 receptor ligands

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07852376

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007297869

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2654438

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 573176

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2009513268

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007852376

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007297869

Country of ref document: AU

Date of ref document: 20070530

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU